129 related articles for article (PubMed ID: 37351978)
1. Effect of Adequate Local Radiation Dose on Oncological Outcomes in Localized Prostate Cancer Patients Treated With Low-dose-rate Brachytherapy.
Enei Y; Urabe F; Miki K; Suzuki H; Iwatani K; Tashiro K; Tsuzuki S; Furuta A; Sasaki T; Sato S; Takahashi H; Aoki M; Kimura T
Anticancer Res; 2023 Jul; 43(7):3159-3166. PubMed ID: 37351978
[TBL] [Abstract][Full Text] [Related]
2. Do androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer?
Tabata R; Kimura T; Kuruma H; Sasaki H; Kido M; Miki K; Takahashi H; Aoki M; Egawa S
Cancer Med; 2016 Sep; 5(9):2314-22. PubMed ID: 27456710
[TBL] [Abstract][Full Text] [Related]
3. Local dose (biologically effective dose ≥180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapy.
Tanaka N; Nakai Y; Asakawa I; Yamaki K; Miyake M; Hori S; Owari T; Fujii T; Fujimoto K
Int J Urol; 2022 Dec; 29(12):1560-1568. PubMed ID: 36125928
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation.
Kadena S; Urabe F; Iwatani K; Suzuki H; Imai Y; Tashiro K; Tsuzuki S; Honda M; Koike Y; Shimomura T; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
Int J Clin Oncol; 2023 Aug; 28(8):1092-1100. PubMed ID: 37227547
[TBL] [Abstract][Full Text] [Related]
5. The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes.
Stock RG; Buckstein M; Liu JT; Stone NN
BJU Int; 2013 Jul; 112(2):E44-50. PubMed ID: 23773225
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy.
Urabe F; Miki K; Kimura T; Sasaki H; Tashiro K; Tsutsumi Y; Morikawa M; Minato K; Sato S; Takahashi H; Aoki M; Egawa S
Prostate; 2022 Mar; 82(4):433-441. PubMed ID: 34914134
[TBL] [Abstract][Full Text] [Related]
7. Treatment Results of High-dose-rate Brachytherapy and External Beam Radiation With Long-term Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer.
Suzuki H; Urabe F; Iwatani K; Miyajima K; Imai YU; Tashiro K; Tsuzuki S; Honda M; Koike Y; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
Anticancer Res; 2023 Jul; 43(7):3135-3143. PubMed ID: 37352008
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
[TBL] [Abstract][Full Text] [Related]
9. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
10. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.
Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K
Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973
[TBL] [Abstract][Full Text] [Related]
11. Effect of adding androgen deprivation therapy to permanent iodine-125 implantation with or without external beam radiation therapy on the outcomes in patients with intermediate-risk prostate cancer: A propensity score-matched analysis.
Sutani S; Yorozu A; Toya K; Shiraishi Y; Nishiyama T; Yagi Y; Nakamura K; Saito S
Brachytherapy; 2021; 20(1):10-18. PubMed ID: 33069598
[TBL] [Abstract][Full Text] [Related]
12. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.
Pickles T; Morris WJ; Keyes M
Brachytherapy; 2017; 16(6):1101-1105. PubMed ID: 29032014
[TBL] [Abstract][Full Text] [Related]
13. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
[TBL] [Abstract][Full Text] [Related]
15. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
[TBL] [Abstract][Full Text] [Related]
16. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
[TBL] [Abstract][Full Text] [Related]
17. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
Kishan AU; Steigler A; Denham JW; Zapatero A; Guerrero A; Joseph D; Maldonado X; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Tilki D; Karnes RJ; Tosoian JJ; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Jiang T; Ma TM; Xiang M; Philipson R; Chang A; Kupelian PA; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Boutros PC; Horwitz EM; Tendulkar RD; Spratt DE; Romero T
JAMA Oncol; 2022 Mar; 8(3):e216871. PubMed ID: 35050303
[TBL] [Abstract][Full Text] [Related]
18. Patient age as a predictive factor in biochemical recurrence following brachytherapy: Oncological outcomes at a single center.
Takeuchi S; Iinuma K; Nakano M; Kawase M; Kato D; Kawase K; Takai M; Nakane K; Ito M; Kumano T; Matsuo M; Koie T
Prostate Int; 2022 Dec; 10(4):224-228. PubMed ID: 36570651
[TBL] [Abstract][Full Text] [Related]
19. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
[TBL] [Abstract][Full Text] [Related]
20. Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis.
Mendez LC; Martell K; Warner A; Tseng CL; Chung H; Loblaw A; Rodrigues GB; Morton G
Radiother Oncol; 2020 Sep; 150():195-200. PubMed ID: 32619455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
